Provided by Tiger Trade Technology Pte. Ltd.

Plus Therapeutics, Inc.

0.2752
+0.01827.08%
Post-market: 0.27690.0017+0.62%19:58 EST
Volume:6.30M
Turnover:1.74M
Market Cap:49.09M
PE:-0.60
High:0.2876
Open:0.2668
Low:0.2600
Close:0.2570
52wk High:2.31
52wk Low:0.1634
Shares:178.37M
Float Shares:178.37M
Volume Ratio:1.01
T/O Rate:3.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4560
EPS(LYR):-1.9544
ROE:-522.50%
ROA:-65.58%
PB:9.71
PE(LYR):-0.14

Loading ...

Plus Therapeutics Approves 2025 Executive Compensation and Bonuses

Reuters
·
Feb 14

Plus Therapeutics (PSTV) Gets a Buy from Lake Street

TIPRANKS
·
Feb 05

Plus Therapeutics initiated with a Buy at Lake Street

TIPRANKS
·
Feb 03

Maxim Group Sticks to Their Buy Rating for Plus Therapeutics (PSTV)

TIPRANKS
·
Jan 23

Plus Therapeutics announces anticipated milestones for FY26

TIPRANKS
·
Jan 22

Plus Therapeutics Inc - Reyobiq Phase 2 Trial Data Expected in Q3 2026

THOMSON REUTERS
·
Jan 22

BRIEF-Plus Therapeutics To Provide Business Update On Thursday

Reuters
·
Jan 22

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

GlobeNewswire
·
Jan 22

Benzinga Bulls And Bears: TSMC, Rocket Lab, J.B. Hunt — And Space Stocks Soar

Benzinga_recent_news
·
Jan 17

BRIEF-Plus Therapeutics Inc - On Jan 13, Co Enters Underwriting Agreement With Lake Street Capital Markets, Llc - SEC Filing

Reuters
·
Jan 17

Plus Therapeutics Inc - to Issue 39,473,684 Shares and Warrants at $0.38 Each - SEC Filing

THOMSON REUTERS
·
Jan 17

Plus Therapeutics Prices Upsized $15 Million Public Offering

MT Newswires Live
·
Jan 15

Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November

Benzinga
·
Jan 15

Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges

Benzinga_recent_news
·
Jan 15

Plus Therapeutics prices 39.5M units at 38c in upsized public offering

TIPRANKS
·
Jan 14

Plus Therapeutics Inc - Each Unit Sold at $0.38, Gross Proceeds Expected $15 Mln

THOMSON REUTERS
·
Jan 14

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

GlobeNewswire
·
Jan 14

BRIEF-Plus Therapeutics Announces Read Out Of Type B Meeting With The FDA

Reuters
·
Jan 08

Plus Therapeutics Announces Read Out of Type B Meeting With the FDA With Goal of Accelerating Approval of Reyobiq™ for Leptomeningeal Metastases

THOMSON REUTERS
·
Jan 08

Plus Therapeutics Inc - FDA Recommends Study Evaluate Endpoint With Clinical Benefit

THOMSON REUTERS
·
Jan 08